Advertisement


Julie Vose, MD, MBA, and Mhairi Copland, MB, ChB, PhD, on CML: Data From the British DESTINY Study

2016 ASH Annual Meeting & Exposition

Advertisement

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Mhairi Copland, MB, ChB, PhD, of the Paul O’Gorman Leukaemia Research Centre at the University of Glasgow, discuss decreasing the dose of tyrosine kinase inhibitors in CML patients with stable molecular responses (Abstract 938).



Related Videos

Leukemia

Syed A. Abutalib, MD, and Nelli Bejanyan, MD, on Adult ALL and Consolidation Chemotherapy: Results From a CIBMTR Study

Syed A. Abutalib, MD, of Cancer Treatment Centers of America, and Nelli Bejanyan, MD, of the University of Minnesota, discuss findings from a study conducted by the Center for International Blood and Marrow Transplant Research on treatment for ALL patients, with an available donor, undergoing myeloablative allogeneic hematopoietic cell transplantation in first complete remission (Abstract 684).

Lymphoma

Jonathon Cohen, MD, and Sagar Lonial, MD, on DLBCL: Results of the CALGB/Alliance 50303 Trial

Jonathon Cohen, MD, and Sagar Lonial, MD, both of Emory University, discuss study findings on R-CHOP vs DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma (Abstract 469).

Lymphoma

Umberto Vitolo, MD, and Sagar Lonial, MD, on DLBCL: Final Results From the GOYA Trial

Umberto Vitolo, MD, of Città della Salute e della Scienza Hospital and University, and Sagar Lonial, MD, of Emory University, discuss study findings on obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (Abstract 470).

Lymphoma
Geriatric Oncology

Catherine Thieblemont, MD, PhD, and Julie Vose, MD, MBA, on DLBCL: Results From the Lysa Remarc Study

Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the first-line setting (Abstract 471).

Leukemia

Martin Schrappe, MD, on Childhood ALL: Study Results on Reducing Treatment Burden

Martin Schrappe, MD, of Christian-Albrechts University Kiel, discusses study findings on reduced intensity delayed intensification in standard-risk patients defined by minimal residual disease in childhood acute lymphoblastic leukemia (Abstract 4).

Advertisement

Advertisement




Advertisement